EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
But what do you do with all this data? Better tracking of blood usage presents a huge opportunity to improve the blood system as a whole. With real-time information about blood products as they move from donation through production, testing and distribution, the blood operator can more quickly and accurately identify areas for improvement.
Blockchain can also facilitate researchers’ access to large data sets, while at the same time protecting the privacy of donors and recipients. That could allow them to correlate patient outcomes with variables such as the gender of their blood donor, or the temperature at which the products they received had been transported. In turn, researchers’ findings could inspire changes to the blood system that benefit patients.
“The work with EY has allowed CBS to imagine a very important advancement in healthcare,” says Rick Prinzen, Chief Supply Chain Officer and Vice President of Donor Relations, CBS. “Connecting donor centre donations with in-hospital transfusions and enabling hospitals to have real-time access to the whole blood component product flow and product status represents a significant advancement in driving supply chain value and improved health outcomes”.
What patterns improve supply efficiency? If issues occur with a particular batch of blood, where exactly did those issues occur, and how can they be prevented in future?
These are just a few examples of the questions that this blockchain-enabled program could answer. And better measurement of the movement and status of blood within these vast blood donation networks promises substantial potential for identifying further improvements in the efficiency of the health service as a whole, making sure that the value of donated blood goes further, and saves even more lives.
With positive health outcomes often dependent on tiny variables in how patients are treated, the increased visibility achieved by putting blood on the blockchain could make a transformative difference.
The program initially launched in trial stages, EY solution is now moving toward implementation in markets beyond Canada.